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‘remission’ states may discontinue treatment. The relative risk of discontinuation
on venlafaxine (2.37 at Week 6) compared with agomelatine is applied to the dis-
continuation rate of venlafaxine in the Australian population. When a patient is off
treatment, they have a reduced likelihood of moving to the ‘remission’ and ‘well’
states compared with patients remaining on treatment. Costs are in 2010 dollars
and costs and outcomes discounted at 5%. RESULTS: Compared with venlafaxine,
treatment with agomelatine yields 0.011 additional quality-adjusted life-years
(QALY) at an incremental cost of AU$196 giving an incremental cost-effectiveness
ratio (ICER) of AU$18,098/QALY. The presentation will discuss the issues raised by
the PBAC and how these were addressed. CONCLUSIONS: When the impact of a
lower discontinuation rate is modelled, agomelatine is a cost-effective treatment
for MDD versus venlafaxine.
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OBJECTIVES: Schizophrenia patients who suffer from frequent relapses have their
cognition damaged and need heavy medical resource utilization such as long-term
hospitalization. Schizophrenia incurs a burden not only to patients and caregivers,
but also to society. This study aims to carry out cost-utility analysis of ‘paliperidone
palmitate long acting injection (PLAI)’ that improves drug adherent compared with
atypical oral antipsychotics (risperidone, olanzapine, aripiprazole and paliperi-
done) from a payer’s perspective. METHODS: The study subjects are non-adherent
schizophrenia patients with exacerbation of symptoms. A decision-tree model was
constructed to compare the clinical and economic outcomes of PLAI and oral com-
parator over 1 year. Clinical data such as relapse rate, EPS rate, suicide rate and
non-adherent rate as well as utility weight were obtained from published litera-
ture. Direct medical cost data were also obtained from a domestic literature. Sen-
sitivity analyses were performed on PLAI drug cost and major variables. RESULTS:
: Based on model estimates, PLAI showed some advantages of reducing hospital-
ization and increasing utility over its comparators. Total direct medical costs were
KRW 5.62million for PLAI, and KRW 4.71million for comparators. Incremental cost-
effectiveness ratio of PLAI versus oral atypical antipsychotics was KRW 2.22million
per quality-adjusted life year (QALY). Sensitivity analyses showed that hospitaliza-
tion cost per day and frequency of hospitalization per year had greatest influence
on the result. CONCLUSIONS: The use of PLAI may result in improved health effect
and QALY compared with atypical antipsychotics. Despite its higher cost, PLAI can
be considered as one of the options for non-adherent patients in schizophrenia, as
it reduces hospitalization and increases quality of life.
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OBJECTIVES: To better understand antidepressant-related weight gain and its as-
sociation with medication adherence in employees experiencing depression.
METHODS: Employed individuals (18 years of age) with diagnosed depression
(excluding bipolar disorder) completed a web-based computer-generated 25-min-
ute survey (population identified by Harris InteractiveTM). Antidepressant adher-
ence was quantified via 8-item Morisky Medication Adherence Scale (MMAS-8)
where scores of 0, 1-2, and 3-8 were categorized as high, medium, and low adher-
ence, respectively. Weight gain was measured using the Toronto Side Effects Scale
which measures medication-related side effects in the 2-weeks preceding the sur-
vey, and analyzed as a 4-level ordinal variable (none,2lbs,4lbs, and7lbs),
where “none” was the referent category. Gender stratified cumulative logit models
were used to estimate effect of weight gain on medication adherence. Binary logit
models were used to estimate effect of weight gain on each of the 8 MMAS-8
questions. RESULTS: Of 1521 survey respondents, 872 (57%) reported current anti-
depressant use (60.6% female, mean age 49.9  13.5 years). A higher proportion of
female patients (39%) belonged to the “low adherence” category compared to male
patients (31%) (p0.02). Compared to males with no weight gain, odds of being in a
poorer overall adherence category were greater in the7lbs weight gain category
(odds ratio [OR]2.33; p 0.09 ); likewise, odds of reporting not taking medication
for “reasons other than forgetting” were greater for 4lbs (OR2.35; p0.05) and
7lbs (OR2.92; p0.04 ). Among female patients, odds of reporting “reductions
or stoppage of medication use” increased with increasing weight gain of 2lbs
(OR1.72; p0.05), 4lbs (OR2.00; p0.06), and 7lbs (OR2.50; p.07).
CONCLUSIONS: These data suggest that antidepressant-related weight gain may
result in diminished adherence to prescribed medication. Additional research
should focus on further quantification of this association as medication non-ad-
herence may be closely associated with depressive relapse.
PMH44
IMPROVING HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH
REFRACTORY POST-TRAUMATIC STRESS DISORDER: USE OF LOCAL
ANESTHETICS SHOW PROMISE IN A CLINICAL CASE SERIES
Lipov EG1, Navaie M2, Stedje-Larsen ET3, Burkhardt K1, Smith JC2, Hickey AH3
1Advanced Pain Centers, S.C., Hoffman Estates, IL, USA, 2Advance Health Solutions, La Jolla, CA,
USA, 3Naval Medical Center San Diego, San Diego, CA, USA
OBJECTIVES: Existing evidence-based treatments for the anxiety condition Post-
Traumatic Stress Disorder (PTSD) have an overall success rate of only 20% to 30%
with pharmacologic therapies. Thus, an urgent need exists for alternative PTSD
treatment options. This investigation examined the impact of local anesthetics
delivered via stellate ganglion block (SGB) injection on mitigating PTSD severity,
thereby improving health-related quality of life (HRQoL). METHODS: A retrospec-
tive case series (n8) who received one (n6) or more (n2) SGB treatments con-
sisting of 0.5% bupivacaine was identified at one private practice setting. A wide
range of demographic and clinical data was extracted from medical records. PTSD
severity and dimensions of HRQoL were examined using standardized valid instru-
ments. T-tests were used to compare mean changes in PTSD severity scores, with
p0.05 denoting significance. RESULTS: The majority of cases were male (88%) and
veterans (63%). The average age was 43.4 years (range, 29 to 66 years). Mean fol-
low-up time after SGB treatment was 17.5 days (range, 1 to 59 days). Among cases
who received one SGB injection, significant improvements in overall PTSD severity
were observed (p0.02) including symptoms related to the psychological dimen-
sions of avoidance (p0.03), and hyperarousal (p0.01). On average, these patients
experienced a 41% decrease in PTSD severity (range, 6% to 70%). Relative to cases
who received one SGB injection, the two cases with multiple SGB injections re-
ported greater levels of PTSD symptom relief (58.6% and 73.4%), with substantial
improvements in all three PTSD-related psychological clusters, namely re-experi-
encing, avoidance, and hyperarousal symptoms. All patients reported substantial
improvements in HRQoL and none experienced adverse events. CONCLUSIONS:
Local anesthetics delivered via SGB show promise as an alternative treatment for
refractory PTSD. Double-blind randomized placebo-controlled trials are needed to
generate further confirmatory evidence for sound clinical decision-making and
health advocacy to expand SGB’s indication for PTSD.
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OBJECTIVES: The SF-6D and the EQ-5D are two ways to generate utility values.
Many studies compared these methods, but there is limited information in schizo-
phrenia. The objective of this study is to compare the SF-36 and EQ-5D utility values
and to compare their evolution over time in European schizophrenic patients.
METHODS: We used data from EuroSC, a multicenter 2-year cohort study con-
ducted in France, England and Germany. In several subpopulations, we used
paired-samples t-test to identify significant differences at baseline, and calculated
the Pearson correlation. Changes from baseline were also calculated at 6 and 24
months. RESULTS:The overall sample was composed of 1088 patients. Mean utility
scores were significantly different at baseline (EQ-5D: 0.73 (0.28); SF-6D: 0.65 (0.09);
p0.0001), and values modestly correlated (r  0.314, p0.001). The SF-6D scores
distribution was found to be normal, contrary to EQ-5D, highly negatively skewed.
Range of values was much larger for EQ-5D (EQ-5D: [-0.35; 1.00]; SF-6D: [0.32; 0.87]).
The difference was also significant at baseline when considering subpopulations,
with higher values for EQ-5D. When considering patients whose illness was stable
or had improved at 6 months, change from baseline was significantly different
from 0 for EQ-5D (mean 0.067 (0.29) p0.0001), but not for SF-6D (0.007 (0.11)
p0.28). The result was not significant for patients whose illness worsened (EQ-5D:
-0.040 (0.29) p0.19; SF-6D: -0.007 (0.12) p0.56). The same trends were observed
after 24 months, using depression scores to evaluate improvement or worsening,
and when adjusted on the baseline value. CONCLUSIONS: In our study, EQ-5D
tends to generate wider and higher scores in schizophrenic patients. EQ-5D seems
to be more sensitive to change than SF-6D. The method by which QALYs have been
computed is of importance in an economic evaluation.
PMH46
THE QUALITY OF LIFE OF CHILDREN WITH ADHD AND THEIR PARENTS:
RESULTS OF EQ-5D AND KIDSCREEN-10
Van Der Kolk A1, Bouwmans C2, Schawo S2, Buitelaar JB3, van der Gaag RJ4,
Van agthoven M1, Hakkaart-van Roijen L2
1Janssen-Cilag B.V., Tilburg, The Netherlands, 2Erasmus University, Rotterdam, The
Netherlands, 3Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands,
4Karakter Universitair Centrum, Nijmegen, The Netherlands
OBJECTIVES:The aim of this study is to describe the Quality of Life (QoL) of children
with Attention Deficit Hyperactivity Disorder (ADHD) and their parents. The objec-
tive was to compare QoL in different states of compliance to medication (methyl-
phenidate and atomoxetine), in remission status after medication use or being
naïve to medication using EQ-5D (proxy version for the children) and KID-
SCREEN-10 (KS) questionnaires. METHODS: A cross-sectional, retrospective, sur-
vey was performed using online questionnaires (September 1, 2010 to October 3,
2010) that was completed by the parent/caregiver. Inclusion criterion was being a
parent/caregiver of a child (age 6-18 years) diagnosed with ADHD. Parents/caregiv-
ers were contacted via the Dutch patient organization. Subgroups of medication
use were defined by parents as ‘optimal’, ‘suboptimal’, ‘remission’ and ‘medication
use stopped’ according to current medication intake. The fifth group were children
who never used ADHD-medication. Qol data of the child and the parent were
compared in these different groups of medication intake, using Students’ t-tests for
continuous variables and Kruskal-Wallis tests for categorical data. RESULTS:Anal-
yses were performed on 873 returned questionnaires. The QoL in the classified
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